Kinaset Therapeutics to Present at the American Thoracic Society (ATS) 2023 Respiratory Innovation Summit
15 May 2023
Phase 1
BOSTON--(BUSINESS WIRE)-- Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced an upcoming presentation at the ATS 2023 Respiratory Innovation Summit being held in Washington D.C. May 19-20, 2023. Robert Clarke, PhD, Chief Executive Officer of Kinaset, will deliver an oral and poster presentation on the latest clinical progress of Kinaset’s lead candidate, KN-002, a novel, pan-JAK inhibitorpan-JAK inhibitor being advanced for the treatment of moderate to severe asthma.
Presentation Details:
Poster Title: Kinaset Therapeutics: A Clinical-Stage Respiratory Disease-Focused Company
Session Title: Showcase One: Asthma, COPD, and AirwayAirway Inflammation Innovators
Session Date and Time: Saturday, May 20 at 8:30 a.m. ET
Location: Marriott Marquis Washington
More information on the ATS 2023 Respiratory Innovation Summit can be found here.
About Kinaset Therapeutics, Inc.
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. The Company’s lead clinical candidate KN-002 is a novel, pan-JAK inhibitorpan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhaled route of administration. KN-002 is currently being evaluated in a Phase 1b clinical study involving patients with mild to severe asthma and those with COPD (NCT05006521). With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company. See more information at the Company’s website.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.